Strativa has made available Oravig (miconazole buccal tablets) for the treatment of oropharyngeal candidiasis (OPC) in patients ≥16 years of age.

The FDA has approved Oravig (miconazole buccal tablets, from Strativa) for the treatment of oropharyngeal candidiasis (OPC) in patients ≥16 years of age. This approval was based on data from two ...

Miconazole buccal tablets are an effective treatment for oropharyngeal candidiasis, although the cost can be prohibitive for some patients, according to an article in the Journal of Patient Preference ...

In addition to 'Oropharyngeal candidiasis', there may be other similar symptoms or signs that better match your side effect. These have also been listed below for your convenience.

Candidiasis: New agents for invasive infections. By Carl Sherman | September 28, 2009 . Candida albicans ©Dennis Kunkel Microscopy, Inc./Visuals Unlimited ...

Considering taking supplements to treat oropharyngeal candidiasis? Below is a list of common natural remedies used to treat or reduce the symptoms of oropharyngeal candidiasis. Follow the links to ...

Sosei Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis. Tuesday, March 12, 2013 General News. Advertisement TOKYO, March 12, 2013 /PRNewswire/ -- ...

Sosei has acquired development and commercialization rights to Loramyc in Japan from BioAlliance Pharma. Loramyc is an antifungal agent administered as a mucoadhesive buccal tablet for treating ...

A bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means of treating oropharyngeal candidiasis, which is the most frequently occurring infection in head ...

* Says its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole 50 mg, muco-adhesive tablet) for the treatment of oropharyngeal candidiasis; meeting ...